Laura Chico

Stock Analyst at Wedbush

(0)
# 4146
Out of 5,218 analysts
231
Total ratings
33.85%
Success rate
-5.37%
Average return
45 Stocks
Name Action Price Target Current % Upside Ratings Updated
Solid Biosciences
Initiates Coverage On: Outperform
16
4.93 224.54% 1 Dec 13, 2024
Edgewise Therapeutic...
Maintains: Outperform
44 45
27.61 62.98% 9 Nov 8, 2024
Vigil Neuroscience
Maintains: Outperform
23 24
1.98 1112.12% 8 Nov 8, 2024
PepGen
Maintains: Outperform
19 12
4.7 155.32% 9 Nov 8, 2024
Vera Therapeutics
Maintains: Neutral
30 38
44 -13.64% 7 Nov 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
29 4
3.86 3.63% 3 Oct 23, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
9 8
5.34 49.81% 8 Oct 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
17 25
17.3 44.51% 9 Oct 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
22
6.16 257.14% 1 Oct 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
210 205
150.04 36.63% 16 Sep 23, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
40 44
n/a n/a 7 Sep 17, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
40 48
69.98 -31.41% 6 Aug 14, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
22 22
9.5 131.58% 8 Aug 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
4 4
0.92 334.78% 3 Aug 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
38 41
33.24 23.35% 13 Aug 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
50 49
40.07 22.29% 8 Aug 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
38 36
23.76 51.52% 5 Aug 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
8 7
6.25 12% 4 Aug 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
30 26
22.96 13.24% 7 Aug 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
43 46
45.88 0.26% 11 Aug 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
11 11
5.21 111.13% 13 Aug 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
42 42
17.77 136.35% 7 Jul 29, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
17 17
12.05 41.08% 6 Jul 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
41 41
2.54 1514.17% 3 Jun 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
152 152
126.68 19.99% 7 May 29, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
35 31
18.51 67.48% 5 May 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
13 11
1.1 900% 4 Apr 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
8
1.03 676.7% 1 Apr 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
5
5.57 -10.23% 5 Mar 20, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
330
n/a n/a 6 Dec 22, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Market Perform
n/a
n/a n/a 5 Sep 28, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
42
n/a n/a 3 Aug 8, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
24 5
n/a n/a 2 Nov 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
9 5
2.06 142.72% 2 Aug 12, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
149
38.47 286.02% 1 Aug 8, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
16
n/a n/a 1 Sep 2, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 4 Feb 8, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
33
n/a n/a 1 Sep 18, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reinstates: Outperform
40
n/a n/a 3 Feb 15, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
240 0
n/a n/a 2 Sep 12, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Outperform
36 0
n/a n/a 2 Mar 2, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 2 Jan 23, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
720
15.13 4658.76% 1 Jan 19, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Underperform
n/a
n/a n/a 1 Nov 16, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Strong Buy
280
23.25 1104.3% 1 Apr 21, 2017